Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 16/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22523798 | 1.00 | CYP2D6 (0.41) | CYP2D6AADATKIF11PTPN11KCNH2 | |
| SCHEMBL24878644 | 0.85 | CYP2D6 (0.40) | CYP2D6PTPN11KCNH2 | |
| SCHEMBL22523752 | 0.85 | CYP2D6 (0.40) | CYP2D6PTPN11KCNH2 | |
| SCHEMBL21940878 | 0.85 | SLC6A3 (0.38) | AADATPTPN11KCNH2 | |
| SCHEMBL21940662 | 0.85 | SLC6A3 (0.38) | AADATPTPN11KCNH2 | |
| SCHEMBL24091090 | 0.81 | KCNH2 (0.41) | AADATPTPN11KCNH2 | |
| SCHEMBL24091164 | 0.81 | KMT2A (0.40) | AADATKIF11PTPN11KCNH2 | |
| SCHEMBL22523803 | 0.81 | KCNH2 (0.41) | AADATPTPN11KCNH2 | |
| SCHEMBL22520446 | 0.79 | CYP2D6 (0.47) | CYP2D6PTPN11KCNH2 | |
| SCHEMBL22520440 | 0.79 | CYP2D6 (0.47) | CYP2D6PTPN11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | CYP2D6 4405/4885AADAT 4024/4885KIF11 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.